RE:RE:Sonodynamic Therapy Explained That would change the revenue stream for Theralase! If as said So, after PDT, that would be our 2nd way of taken advantage of the amazing potency of our PDCs to destroy tumors, no matter where they are in the body, for example in deep-seated tissues/organs.
In 2020 worldwide Bladder cancer patients were 573,000 and 75% of that was 430,000 for NMIBC if sonodynamic treatment could reach MIBC along with the NMIBC then the revenue stream would grow.
In a hypothetical first year of commercialization worldwide Theralase treatment might get 10% (43,000 patients) for NMIBC however if SDT can also be factored into the revenue stream then at 10% (14,300 patients) that would be 57,000.
This hypothetical revenue of a 10% market share at $50,000 per treatment for the 43,000 = 2.15B at 2 treatments that would be 4.3B
Still only looking at 10% of worldwide cases for MIBC and if Theralase is successful the 14,300 patients would add to the revenue stream $50,000 × 14,300 = 715M for 1 treatment.
Unknown is gross expenses to Theralase or the JV partnership but revenue for 10% of gross market share would be well over a billion.